Agios Pharmaceuticals, Inc. (AGIO) SEC Filings & Earnings Calls

Generic competition risk for mitapivat

“on February 17, 2026 a sponsor submitted an ANDA for mitapivat with a Paragraph IV certification listing patents that it intends to challenge” · word for word

Commercialization execution risk

“If we do not successfully commercialize PYRUKYND®, AQVESME™ and other products for which we receive approval, our prospects may be substantially harmed.” · word for word

Clinical trial failure risk

“Clinical trials of our product candidates may not be successful for a number of important reasons.” · word for word

Liquidity risk

“If our existing capital is insufficient to fund our operating expenses and capital expenditures, we will need to raise capital, and if we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts.” · word for word

Pipeline discontinuation of tebapivat in LR-MDS and sickle cell disease indicates R&D risk.

“Agios announced that it will not advance tebapivat in LR-MDS or sickle cell disease following Phase 2 results.” · word for word

Dependence on mitapivat for near-term revenue; single product concentration risk.

“All product revenue is from mitapivat; no other approved products.”

Potential dilution from increased share authorization, but standard for biotech.

“2,000,000 additional shares authorized under 2023 Stock Incentive Plan.”

Net loss widened due to increased R&D and SG&A expenses.

“Net loss was $99.1 million, compared to $89.3 million in Q1 2025.” · word for word

Generic competition risk for mitapivat

“on February 17, 2026 a sponsor submitted an ANDA for mitapivat with a Paragraph IV certification listing patents that it intends to challenge” · word for word

Commercialization execution risk

“If we do not successfully commercialize PYRUKYND®, AQVESME™ and other products for which we receive approval, our prospects may be substantially harmed.” · word for word

Clinical trial failure risk

“Clinical trials of our product candidates may not be successful for a number of important reasons.” · word for word

Liquidity risk

“If our existing capital is insufficient to fund our operating expenses and capital expenditures, we will need to raise capital, and if we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts.” · word for word

Litigation risk from securities class actions

“In February and March 2024, three putative securities class action lawsuits were filed and subsequently consolidated as In re agilon health, inc. Securities Litigation... The Consolidated Securities Matter seeks compensatory damages, judgment interest, attorney’s fees and costs, and other unspecified equitable and/or injunctive relief.”

Net loss widening due to higher R&D spend

“Net loss $108M vs $96.5M; R&D expenses increased to $88.1M from $82.8M.”

Regulatory and commercial execution risk for AQVESME launch

“AQVESME launch just started; REMS program implemented; thalassemia market adoption uncertain.”

Commercialization risk for AQVESME

“If we do not successfully commercialize PYRUKYND®, AQVESME™ and other products for which we may receive approval, our prospects may be substantially harmed.” · word for word

Clinical trial failure risk

“Clinical trials of our product candidates may not be successful for a number of important reasons.” · word for word

Capital needs and operating losses

“We have historically incurred operating losses. We expect to incur losses in the future and may never achieve or maintain profitability.” · word for word

AQVESME carries a boxed warning for hepatocellular injury, requiring REMS program.

“BOXED WARNING: HEPATOCELLULAR INJURY... AQVESME can cause serious hepatocellular injury.” · word for word

Regulatory and clinical trial risks for mitapivat in sickle cell disease and other indications.

“pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated... topline results from Phase 2 trial expected H2 2026” · word for word

Net loss of $103.4M driven by R&D investment; prior year had non-recurring milestone income

“Net loss was $103.4 million dollars, compared to net income of $947.9 million dollars for the quarter ended September 30, 2024” · word for word

Regulatory risk: PDUFA extension due to REMS request

“FDA extended PDUFA goal date by three months due to REMS request”

Regulatory delay for thalassemia approval

“The FDA accepted the sNDA and granted a PDUFA goal date of September 7, 2025, which the FDA subsequently extended to December 7, 2025 following our submission of a proposed REMS to mitigate the risk of hepatocellular injury.” · word for word

Safety concern - hepatocellular injury

“In January 2025, the USPI for PYRUKYND® for the treatment of hemolytic anemia in adults with PK deficiency was updated to include information regarding hepatocellular injury observed in clinical trials in patients with thalassemia treated with PYRUKYND® at a higher dose than recommended for patients with PK deficiency.” · word for word